[go: up one dir, main page]

Biswas et al., 2017 - Google Patents

Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1. 7 Inhibitory GpTx-1 Peptide–Antibody Conjugates

Biswas et al., 2017

View PDF
Document ID
2924274739199576869
Author
Biswas K
Nixey T
Murray J
Falsey J
Yin L
Liu H
Gingras J
Hall B
Herberich B
Holder J
Li H
Ligutti J
Lin M
Liu D
Soriano B
Soto M
Tran L
Tegley C
Zou A
Gunasekaran K
Moyer B
Doherty L
Miranda L
Publication year
Publication venue
ACS chemical biology

External Links

Snippet

The voltage-gated sodium channel NaV1. 7 is a genetically validated pain target under investigation for the development of analgesics. A therapeutic with a less frequent dosing regimen would be of value for treating chronic pain; however functional NaV1. 7 targeting …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Biswas et al. Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1. 7 Inhibitory GpTx-1 Peptide–Antibody Conjugates
Wells et al. Extracellular targeted protein degradation: an emerging modality for drug discovery
Fadzen et al. Perfluoroarene–based peptide macrocycles to enhance penetration across the blood–brain barrier
Leong et al. An anti-B7-H4 antibody–drug conjugate for the treatment of breast cancer
Kubetzko et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5
Sadowsky et al. Development of efficient chemistry to generate site-specific disulfide-linked protein–and peptide–payload conjugates: application to THIOMAB antibody–drug conjugates
Simon et al. Orthogonal assembly of a designed ankyrin repeat protein–cytotoxin conjugate with a clickable serum albumin module for half-life extension
Chio et al. Site-specific bioconjugation and multi-bioorthogonal labeling via rapid formation of a boron–nitrogen heterocycle
Puthenveetil et al. Development of solid-phase site-specific conjugation and its application toward generation of dual labeled antibody and fab drug conjugates
Chew et al. CD98hc is a target for brain delivery of biotherapeutics
Ackerman et al. Cystine-knot peptides: emerging tools for cancer imaging and therapy
Matsuda et al. Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of antibody–drug conjugates
Byeon et al. Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis
BR112016017649B1 (en) ISOLATED POLYPEPTIDE COMPRISING MATRIPTASE AND PLASMINOGEN ACTIVATOR U SUBSTRATES AND OTHER CLEAABLE MOTIONS, PHARMACEUTICAL COMPOSITION COMPRISING SAID POLYPEPTIDE, AS WELL AS METHODS FOR PRODUCING AND MANUFACTURING AN ISOLATED POLYPEPTIDE COMPRISING A CLEAABLE MOTION AND USE OF THE PHARMACEUTICAL COMPOSITION AND THERAPEUTICLY EFFECTIVE AMOUNT OF SAID COMPOSITION IN THE TREATMENT OF A DISORDER OR ILLNESS
Zheng et al. Investigating the degradation behaviors of a therapeutic monoclonal antibody associated with pH and buffer species
Park et al. Peptide-directed photo-cross-linking for site-specific conjugation of IgG
Murray et al. Engineering NaV1. 7 inhibitory JzTx-V peptides with a potency and basicity profile suitable for antibody conjugation to enhance pharmacokinetics
Hoffmann et al. PK modulation of haptenylated peptides via non-covalent antibody complexation
Aubrey et al. Site-specific conjugation of auristatins onto engineered scFv using second generation maleimide to target HER2-positive breast cancer in vitro
Cavaco et al. Conjugation of a blood brain barrier peptide shuttle to an Fc domain for brain delivery of therapeutic biomolecules
Farrell et al. The PfRCR complex bridges malaria parasite and erythrocyte during invasion
Jäger et al. Generation and biological evaluation of Fc antigen binding fragment-drug conjugates as a novel antibody-based format for targeted drug delivery
CN113891731A (en) Drug conjugates and methods of use
de Bever et al. Generation of DAR1 antibody-drug conjugates for ultrapotent payloads using tailored GlycoConnect technology
Marquard et al. Expanding the scope of antibody rebridging with new pyridazinedione–TCO constructs